The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
An interval of fewer than 30 days between the last immunotherapy dose and the liver transplant increases the rejection risk ...
Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback